Amivantamab  (Synonyms: JNJ-61186372)

Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

EGFR & c-Met

Amivantamab (JNJ-61186372)(0.05-1 mg/mL) results in a significant and dose-dependent decrease in the viability of Ba/F3 cells, as well as a significant decrease in phosphorylated EGFR (pEGFR), phosphorylated AKT (pAKT), phosphorylated ERK (pERK) and phosphorylated S6 (pS6) of the EGFR downstream signaling pathway^[2].
Amivantamab (JNJ-61186372) has potent antitumor activity in NSCLC patient-derived cancer cells with EGFR Exon20ins mutations through downregulation of EGFR and MET signaling pathways^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Amivantamab (JNJ-61186372)(i.p, 30 mg/kg, twice a week, 15 days)effectively reduces tumour volume in female thymus-free BALB-c/nu mouse xenograft model of NSCLC with EGFR Exon20ins mutation and has in vivo anti-tumour effects^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1956  [NCBI] & 4233  [NCBI]

P00533 & P08581

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.88 kDa

2171511-58-1

Liquid

Colorless to light yellow

[Amivantamab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human c-MET/HGFR Protein (ECD, His Tag) can bind Amivantamab. The EC₅₀ for this effect is 1.20 ng/mL.
• 
  Immobilized Human EGFR Protein can bind Amivantamab. The EC₅₀ for this effect is 2.58 ng/mL.

• [1]. Keunchil Park, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402.   [Content Brief]

  [2]. Jiyeon Yun, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.   [Content Brief]